Total Payments
$39,035
2024 Payments
$6,979
Companies
103
Transactions
1,738
Medicare Patients
26,783
Medicare Billing
$10.0M
Payment Breakdown by Category
Food & Beverage$31,505 (80.7%)
Research$5,095 (13.1%)
Consulting$1,800 (4.6%)
Education$635.19 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $31,505 | 1,696 | 80.7% |
| Unspecified | $5,095 | 28 | 13.1% |
| Consulting Fee | $1,800 | 1 | 4.6% |
| Education | $635.19 | 13 | 1.6% |
Payments by Type
General
$33,940
1,710 transactions
Research
$5,095
28 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $5,095 | 28 | $0 (2024) |
| Celgene Corporation | $2,942 | 57 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,830 | 151 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,478 | 142 | $0 (2024) |
| Amgen Inc. | $1,920 | 85 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,884 | 126 | $0 (2024) |
| Genentech USA, Inc. | $1,716 | 116 | $0 (2024) |
| PFIZER INC. | $1,637 | 107 | $0 (2024) |
| Janssen Biotech, Inc. | $1,330 | 81 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,319 | 77 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,979 | 225 | Regeneron Pharmaceuticals, Inc. ($1,966) |
| 2023 | $6,001 | 222 | Regeneron Pharmaceuticals, Inc. ($1,695) |
| 2022 | $6,262 | 252 | Regeneron Pharmaceuticals, Inc. ($1,434) |
| 2021 | $4,089 | 211 | GENZYME CORPORATION ($368.90) |
| 2020 | $5,054 | 178 | Celgene Corporation ($1,922) |
| 2019 | $3,825 | 233 | Novartis Pharmaceuticals Corporation ($445.93) |
| 2018 | $3,545 | 211 | Novartis Pharmaceuticals Corporation ($506.80) |
| 2017 | $3,281 | 206 | Amgen Inc. ($423.86) |
All Payment Transactions
1,738 individual payment records from CMS Open Payments — Page 1 of 70
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: ONC | ||||||
| 12/18/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: Immunology | ||||||
| 12/16/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Oncology | ||||||
| 12/16/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $1,966.06 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/12/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $23.22 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.92 | General |
| Category: Hematology | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $19.58 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $38.84 | General |
| Category: Oncology | ||||||
| 12/06/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $29.48 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo, Stivarga | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Oncology | ||||||
| 12/02/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: DESMOID TUMORS | ||||||
| 12/02/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/28/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $23.44 | General |
| 11/26/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Oncology | ||||||
| 11/25/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: BioOncology | ||||||
| 11/13/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $5,095 | 28 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 945 | 1,690 | $418,020 | $141,009 |
| 2022 | 83 | 7,939 | 186,838 | $8.8M | $3.0M |
| 2021 | 88 | 9,101 | 262,212 | $9.1M | $3.4M |
| 2020 | 96 | 8,798 | 280,356 | $9.4M | $3.5M |
Total Patients
26,783
Total Services
731,096
Medicare Billing
$10.0M
Procedure Codes
277
All Medicare Procedures & Services
277 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 264 | 627 | $154,869 | $53,167 | 34.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 100 | 184 | $66,976 | $23,264 | 34.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 313 | 395 | $64,780 | $21,852 | 33.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 63 | 206 | $32,960 | $12,337 | 37.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 73 | 73 | $37,595 | $10,748 | 28.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 49 | 60 | $26,880 | $7,750 | 28.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 29 | 78 | $17,706 | $6,983 | 39.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $8,080 | $2,171 | 26.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 16 | $5,136 | $1,575 | 30.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 21 | 31 | $3,038 | $1,163 | 38.3% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 19 | 17,600 | $1.8M | $740,301 | 42.1% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2022 | 16 | 21,200 | $1.2M | $493,079 | 42.3% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2022 | 12 | 7,920 | $792,000 | $286,709 | 36.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 54 | 9,780 | $285,000 | $162,969 | 57.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 515 | 1,739 | $312,879 | $155,331 | 49.6% |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 2022 | 16 | 3,321 | $664,200 | $138,992 | 20.9% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2022 | 56 | 6,200 | $372,000 | $117,110 | 31.5% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2022 | 19 | 3,230 | $403,750 | $106,902 | 26.5% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2022 | 25 | 794 | $522,534 | $103,164 | 19.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 762 | 1,477 | $170,572 | $87,420 | 51.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 116 | 480 | $76,800 | $76,429 | 99.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 131 | 669 | $231,474 | $66,103 | 28.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2022 | 17 | 17,453 | $209,436 | $44,240 | 21.1% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2022 | 188 | 240 | $156,000 | $40,587 | 26.0% |
| J3315 | Injection, triptorelin pamoate, 3.75 mg | Office | 2022 | 25 | 135 | $168,750 | $35,963 | 21.3% |
About Dr. David Ellison, M.D
Dr. David Ellison, M.D is a Hematology & Oncology healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740235928.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Ellison, M.D has received a total of $39,035 in payments from pharmaceutical and medical device companies, with $6,979 received in 2024. These payments were reported across 1,738 transactions from 103 companies. The most common payment nature is "Food and Beverage" ($31,505).
As a Medicare-enrolled provider, Ellison has provided services to 26,783 Medicare beneficiaries, totaling 731,096 services with total Medicare billing of $10.0M. Data is available for 4 years (2020–2023), covering 277 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Charleston, SC
- Active Since 05/24/2006
- Last Updated 09/30/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1740235928
Products in Payments
- LIBTAYO (Biological) $6,147
- KEYTRUDA (Biological) $2,421
- Rituxan (Drug) $1,800
- OPDIVO (Biological) $1,152
- IBRANCE (Drug) $581.34
- Lenvima (Drug) $543.68
- CALQUENCE (Drug) $517.58
- KISQALI (Drug) $510.64
- IMBRUVICA (Drug) $399.66
- JAKAFI (Drug) $395.59
- DARZALEX (Biological) $378.14
- ZEPZELCA (Drug) $358.03
- PADCEV (Biological) $356.79
- AFINITOR (Drug) $350.91
- FOTIVDA (Drug) $348.18
- XTANDI (Drug) $327.90
- REBLOZYL (Biological) $297.01
- VERZENIO (Drug) $292.16
- VENCLEXTA (Drug) $287.78
- SARCLISA (Biological) $281.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Charleston
Mr. George Geils, M.d, M.D
Hematology & Oncology — Payments: $184,021
Hematology & Oncology $184,021
Dr. Albert Lockhart, Md, MD
Hematology & Oncology — Payments: $36,997
Hematology & Oncology $36,997
Dr. Irl Greenwell, M.d, M.D
Hematology & Oncology — Payments: $30,803
Hematology & Oncology $30,803
Dr. Brian Lingerfelt, Md, MD
Hematology & Oncology — Payments: $30,721
Hematology & Oncology $30,721
Robert Stuart, Md, MD
Hematology & Oncology — Payments: $25,933
Hematology & Oncology $25,933
Dr. George Keogh, M.d, M.D
Hematology & Oncology — Payments: $18,248
Hematology & Oncology $18,248